Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Patients with risk factors have higher plasma levels of lysophosphatidic acid: a promising surrogate marker for blood platelet activation.

Yao CS, Yan SG, Gao LS, Sun ZR, Liu F, Jiang B, Wang HB, Wu QZ.

Blood Coagul Fibrinolysis. 2014 Jun;25(4):322-5. doi: 10.1097/MBC.0000000000000034.

PMID:
24346355
2.

Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases.

Li ZG, Yu ZC, Wang DZ, Ju WP, Zhan X, Wu QZ, Wu XJ, Cong HM, Man HH.

Neurol Res. 2008 May;30(4):366-9. doi: 10.1179/174313208X300369.

PMID:
18544253
3.

Possible involvement of minor lysophospholipids in the increase in plasma lysophosphatidic acid in acute coronary syndrome.

Kurano M, Suzuki A, Inoue A, Tokuhara Y, Kano K, Matsumoto H, Igarashi K, Ohkawa R, Nakamura K, Dohi T, Miyauchi K, Daida H, Tsukamoto K, Ikeda H, Aoki J, Yatomi Y.

Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):463-70. doi: 10.1161/ATVBAHA.114.304748. Epub 2014 Nov 25.

4.

The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors.

Haserück N, Erl W, Pandey D, Tigyi G, Ohlmann P, Ravanat C, Gachet C, Siess W.

Blood. 2004 Apr 1;103(7):2585-92. Epub 2003 Nov 26.

5.

The bioactive phospholipid lysophosphatidic acid is released from activated platelets.

Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH.

Biochem J. 1993 May 1;291 ( Pt 3):677-80.

6.

Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood.

Sano T, Baker D, Virag T, Wada A, Yatomi Y, Kobayashi T, Igarashi Y, Tigyi G.

J Biol Chem. 2002 Jun 14;277(24):21197-206. Epub 2002 Apr 2.

7.

Lysophosphatidic acid-induced platelet shape change revealed through LPA(1-5) receptor-selective probes and albumin.

Khandoga AL, Fujiwara Y, Goyal P, Pandey D, Tsukahara R, Bolen A, Guo H, Wilke N, Liu J, Valentine WJ, Durgam GG, Miller DD, Jiang G, Prestwich GD, Tigyi G, Siess W.

Platelets. 2008 Sep;19(6):415-27. doi: 10.1080/09537100802220468.

8.

Lysophosphatidic acid level and the incidence of silent brain infarction in patients with nonvalvular atrial fibrillation.

Li ZG, Yu ZC, Yu YP, Ju WP, Wang DZ, Zhan X, Wu XJ, Zhou L.

Int J Mol Sci. 2010 Oct 19;11(10):3988-98. doi: 10.3390/ijms11103988.

9.

Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway.

Pamuklar Z, Lee JS, Cheng HY, Panchatcharam M, Steinhubl S, Morris AJ, Charnigo R, Smyth SS.

Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):555-61. doi: 10.1161/ATVBAHA.107.151837. Epub 2008 Jan 17.

10.

Increased lysophosphatidic acid levels in culprit coronary arteries of patients with acute coronary syndrome.

Dohi T, Miyauchi K, Ohkawa R, Nakamura K, Kurano M, Kishimoto T, Yanagisawa N, Ogita M, Miyazaki T, Nishino A, Yaginuma K, Tamura H, Kojima T, Yokoyama K, Kurata T, Shimada K, Daida H, Yatomi Y.

Atherosclerosis. 2013 Jul;229(1):192-7. doi: 10.1016/j.atherosclerosis.2013.03.038. Epub 2013 Apr 22.

PMID:
23664202
11.

Serum lysophosphatidic acid is produced through diverse phospholipase pathways.

Aoki J, Taira A, Takanezawa Y, Kishi Y, Hama K, Kishimoto T, Mizuno K, Saku K, Taguchi R, Arai H.

J Biol Chem. 2002 Dec 13;277(50):48737-44. Epub 2002 Sep 26.

12.
13.

The influence of lysophosphatidic acid on platelet protein phosphorylation.

Gerrard JM, Beattie LL, McCrae JM, Singhroy S.

Biochem Cell Biol. 1987 Jul;65(7):642-50.

PMID:
3435662
14.

Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.

Sedláková I, Vávrová J, Tošner J, Hanousek L.

Tumour Biol. 2011 Apr;32(2):311-6. doi: 10.1007/s13277-010-0123-8.

PMID:
21061112
15.

Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.

Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G.

JAMA. 1998 Aug 26;280(8):719-23.

PMID:
9728644
16.

Lysophosphatidic acid is the unique platelet-activating substance in human malignant ascites.

Sandmann G, Siess W, Essler M.

Eur J Med Res. 2003 Sep 29;8(9):397-404.

PMID:
14555295
17.

Increased circulating plasma lysophosphatidic acid in patients with acute coronary syndrome.

Dohi T, Miyauchi K, Ohkawa R, Nakamura K, Kishimoto T, Miyazaki T, Nishino A, Nakajima N, Yaginuma K, Tamura H, Kojima T, Yokoyama K, Kurata T, Shimada K, Yatomi Y, Daida H.

Clin Chim Acta. 2012 Jan 18;413(1-2):207-12. doi: 10.1016/j.cca.2011.09.027. Epub 2011 Sep 29.

PMID:
21983165
18.

Lysophosphatidic acid: an ovarian cancer marker.

Sedláková I, Vávrová J, Tosner J, Hanousek L.

Eur J Gynaecol Oncol. 2008;29(5):511-4.

PMID:
19051824
19.

Diagnostic value of plasma lysophosphatidic acid levels in ovarian cancer patients: A case-control study and updated meta-analysis.

Cao L, Zhang Y, Fu Z, Dong L, Yang S, Meng W, Li Y, Zhang W, Zhang J, Zheng C, Zhu H, Fan L.

J Obstet Gynaecol Res. 2015 Dec;41(12):1951-8. doi: 10.1111/jog.12806. Epub 2015 Oct 16.

PMID:
26472266
20.

Synergistic activation of human platelets by lysophosphatidic acid and adrenaline.

Nilsson U, Svensson SP, Grenegård M.

Haematologica. 2002 Jul;87(7):730-9; discussion 739.

Supplemental Content

Support Center